Ajanta Pharma
Chairman:
Mannalal Agarwal
Vice
Chairman : Purushottam Agarwal
Managing
director : Rakesh Agarwal
Joint
managing director : Yogesh Agarwal
Auditors
: Kapoor & Parekh Associates
Cost
auditors : Seveleari Khare & associates
HISTORY:
It was founded in
1973. It is an Indian multinational, engaged in
development, manufacture and marketing. of
pharmaceutical formulations worldwide, with its headquarters in Mumbai. Ajanta
Pharma has rich experience of over 4 decades in pharma industry with impeccable
record of quality.
BUSINESS MODEL:
APL
has presence in the fast-growing specialty therapeutic segments of Cardiology,
Dermatology, Ophthalmology and Pain management and has been consistently
improving its ranking over the years. Company has been launching many new
products for providing patient compliance and convenience, which is enabling it
to enjoy superior ranking in its therapeutic segments and leadership in some of the sub-therapeutic segments it
operates in.
Company’s
clear focus on specialty segments of Ophthalmology, Dermatology and
Cardiovascular has enabled it to continue to grow at much higher rates over
industry average growth rate of the Indian Pharmaceutical Market (IPM) for last
5 years.
Company has 300 scientists who are working for making innovative products. Employee cost of the company is 13% of sales.
FINANCIAL:
Ajanta Pharma
Limited has been listed on Forbes Asia's 'Best Under a Billion' 2014 list.
Financial Report for FY
2013-2014
In Crores
|
|||
2013
|
2014
|
GROWTH
|
|
Sales
|
8,392.00
|
11,099.20
|
32%
|
Total Income
|
936.44
|
1,222.05
|
30%
|
EBIT
|
224.49
|
368.75
|
64%
|
PBT
|
176.79
|
329.85
|
87%
|
PAT
|
112.11
|
233.88
|
109%
|
EPS
|
31.91
|
66.54
|
109%
|
A
dividend of Rs. 10 per equity share on the face value of Rs. 5 was given for
the year ended 31st March 2014
Quarterly Report
In Crores
|
|||
JAS'13
|
JAS'14
|
GROWTH
|
|
SALES
|
2,798.30
|
3,373.00
|
21%
|
TOTAL INCOME
|
2,861.30
|
3,532.00
|
23%
|
PBT
|
792.60
|
1,130.90
|
43%
|
PAT
|
558.10
|
786.30
|
41%
|
EPS
|
15.79
|
22.35
|
42%
|
FUTURE GROWTH:
According to me, the stock price of this company will rise to about
30-40% because most of the resources are allocated towards R & D. Ajanta Pharma has introduced more than 100 products which were
introduced for the first time, hence there is scope for invention of more
products in the future which will eventually bring more profits to the company.
There has also been continuous growth every year in the company’s financials
for the last 5 years.
Ajanta Pharma was trading at 888 on 10 jan, 2014 and is currently trading at almost thrice in a year time.
Company is currently trading at Rs.2417 at 31.52PE whereas the industry PE is 23.55 which is fair considering a growth rate of 42% in EPS in last quarter.
Net Profit Margin is approx 20% is very good.
We are expecting the share to go upto Rs.3000 on estimated EPS of Rs.100 at 30 PE
Presented
by: Athish Mendon, MMS student of SVIMS college
No comments:
Post a Comment